IL6 and infection: Finally, it was noted that some DMARDs, particularly those that target the IL‐6 pathway (e.g. tocilizumab), and possibly JAK inhibitors, may dampen the acute phase response, and therefore clinicians should remain vigilant to the possibility of infection even in the presence of normal inflammatory markers.